Compare Novavax Inc (NVAX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 28.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| NVAX | VCSH | |
|---|---|---|
Market Cap | $1.82B | $51.90B |
Volume | 6,198,505 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $12.75 | $80.20 |
52-Week Low | $6.22 | $77.03 |
Typical Hold Time | 59 Days | 52 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
VCSH trades at $77.34, showing minimal daily movement with a 0.09% gain. Technical indicators signal a bearish trend overall, with moving averages suggesting selling pressure while oscillators remain neutral. The ETF maintains consistent $0.30 dividend payments scheduled through October 2026. Recent news coverage highlights VCSH's competitive 0.03% expense ratio and 4.5-4.8% dividend yield compared to peer funds.
VCSH offers exposure to short-term investment-grade corporate bonds with minimal interest rate risk due to its 2.7-year duration. The primary risk involves credit spread compression limiting near-term upside potential. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
